Psychiatric Safety of GLP‐1 and Dual GIP/GLP‐1 Receptor Agonists in Adolescents With Obesity
Sep 2026 · Diabetes, obesity and metabolism · Vol 28, pp. 11384 - 11393 · 0 citations
· 43 references
Medicine
Abstract
Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and dual GIP/GLP‐1 receptor agonists are increasingly used for adolescent obesity, but concerns persist regarding psychiatric adverse events, particularly suicidality.